Multicentre evaluation of in vitro contracture testing with bolus administration of 4-chloro-m-cresol for diagnosis of malignant hyperthermia susceptibility

European Journal of Anaesthesiology

Volumn 20, Issue 7, 2003, Pages 528-536

  Wappler, Frank ^a   Anetseder, M ^b   Baur, C P ^c   Censier, K ^d   Doetsch, S ^e   Felleiter, P ^f   Fiegel, M ^a   Fricker, R ^f   Halsall, P J ^g   Hartung, E ^b,l   Heffron, J J A ^h   Heytens, L ⁱ   Hopkins, P M ^g   Klingler, W ^c   Lehmann Horn, F ^c   Nivocheli, Y ^j   Tegazzin, V ^k   Tzanova, I ^e   Urwyler, A ^d   Weisshorn R ^a   Schulte am Esch, J ^a   more..

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c UNIVERSITY OF ULM   (Germany)

^d UNIVERSITY OF BASEL   (Switzerland)

^e JOHANNES GUTENBERG UNIVERSITY   (Germany)

^f UNIVERSITY OF VIENNA   (Austria)

^g UNIVERSITY OF LEEDS   (United Kingdom)

^h UNIVERSITY COLLEGE CORK   (Ireland)

ⁱ UNIVERSITY OF ANTWERP   (Belgium)

^j University of Paris   (France)

^k Department of Anaesthesiology   (Italy)

^l Hospital of Stralsund   (Germany)

more..

Author keywords

Anaesthetics, Inhalation, halothane; Malignant hyperthermia; Muscle, muscle fibres; Organic chemicals, cresols, phenols; Purines, caffeine, purinones, xanthines

Indexed keywords

CAFFEINE; CHLOROCRESOL; HALOTHANE;

ACCURACY; ARTICLE; CALCULATION; CLINICAL PROTOCOL; CONCENTRATION (PARAMETERS); CONTRACTURE; CONTROLLED STUDY; DISEASE PREDISPOSITION; EUROPE; EVALUATION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALIGNANT HYPERTHERMIA; MUSCLE CONTRACTURE; MUSCLE TISSUE; STANDARD;

EID: 0038608881     PISSN: 02650215     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003643-200307000-00003     Document Type: Article

References (33)

1. Wappler F. Malignant hyperthermia. Eur J Anaesthesiol 2001; 18: 632-652.
2. Mickelson JR, Gallant EM, Litterer LA, Johnson KM, Rempel WE, Louis CF. Abnormal sarcoplasmic reticulum ryanodine receptor in malignant hyperthermia. J Biol Chem 1988; 263: 9310-9315.
3. Fill M, Coronado R, Mickelson JR, et al. Abnormal ryanodine receptor channels in malignant hyperthermia. Biophys J 1990; 57: 471-475.
4. Pessah IN, Lynch C, Gronert GA. Complex pharmacology of malignant hyperthermia. Anesthesiology 1996; 84: 1275-1279.
5. Coronado R, Morrissette J, Sukhareva M, Vaughan DM. Structure and function of ryanodine receptors. Am J Physiol 1994; 266: C1485-C1504.
6. Kalow W, Britt BA, Terreau ME, Haist C. Metabolic error of muscle metabolism after recovery from malignant hyperthermia. Lancet 1970; ii: 895-898.
7. Ellis FR, Harriman DGF, Keaney NP, et al. Halothane-induced muscle contracture as a cause of hyperpyrexia. Br J Anaesth 1971; 43: 721-722.
8. European Malignant Hyperpyrexia Group. A protocol for the investigation of malignant hyperpyrexia (MH) susceptibility. Br J Anaesth 1984; 56: 1267-1269.
9. Larach MG, North American Malignant Hyperthermia Group. Standardization of the caffeine halothane muscle contracture test. Anesth Analg 1989; 69: 511-515.
10. Ørding H, Brancadoro V, Cozzolino S, et al. In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European MH Group: results of testing patients surviving fulminant MH and unrelated low-risk subjects. The European Malignant Hyperthermia Group. Acta Anaesthesiol Scand 1997; 41: 955-966.
11. Allen GC, Larach MG, Kunselman AR. The sensitivity and specificity of the caffeine-halothane contracture test: a report from the North American malignant hyperthermia registry. Anesthesiology 1998; 88: 579-588.
12. Isaacs H, Badenhorst M. False-negative results with the muscle caffeine halothane contracture testing for malignant hyperthermia. Anesthesiology 1993; 79: 5-9.
13. Wedel DJ, Nelson TE. Malignant hyperthermia-diagnostic dilemma: false-negative contracture responses with halothane and caffeine alone. Anesth Analg 1994; 78: 787-792.
14. 2+ release channel. J Biol Chem 1987; 343: 559-561.
15. Hopkins PM, Ellis FR, Halsall PJ. Ryanodine contracture: a potentially specific in vitro diagnostic test for malignant hyperthermia. Br J Anaesth 1991; 66: 611-613.
16. Wappler F, Roewer N, Köchling A, Scholz J, Steinfath M, Schulte am Esch J. In vitro diagnosis of malignant hyperthermia susceptibility with ryanodine-induced contractures in human skeletal muscles. Anesth Analg 1996; 82: 1230-1236.
17. Hartung E, Koob M, Anetseder M, et al. Malignant hyperthermia (MH) diagnostics: a comparison between the halothane-caffeine- and the ryanodine-contracture-test results in MH susceptible, normal and control muscle. Acta Anaesthesiol Scand 1996; 40: 437-444.
18. Hopkins PM, Hartung E, Wappler F, European MH Group. Multicentre evaluation of ryanodine contracture testing in malignant hyperthermia. Br J Anaesth 1998; 80: 389-394.
19. 2+ release. Mol Pharmacol 1993; 44: 1192-1201.
20. Herrmann-Frank A, Richter M, Sarközi S, Mohr U, Lehmann-Horn F. 4-Chloro-m-cresol, a potent and specific activator of the skeletal muscle ryanodine receptor. Biophys Biochim Acta 1996; 1289: 31-40.
21. Herrmann-Frank A, Richter M, Lehmann-Horn F. 4-Chloro-m-cresol: a specific tool to distinguish between malignant hyperthermia-susceptible and normal muscle. Biochem Pharmacol 1996; 52: 149-155.
22. Galloway GJ, Denborough MA. Suxamethonium chloride and malignant hyperpyrexia. Br J Anaesth 1986; 58: 447-450.
23. 2+ channel. Anesthesiology 1996; 84: 1380-1385.
24. Wappler F, Scholz J, von Richthofen V, Fiege M, Steinfath M, Schulte am Esch J. 4-Chloro-m-cresol induziert Kontrakturen an Skelettmuskelpräparaten von Patienten mit Disposition zu maligner Hyperthermie. Anästhesiol Intensivmed Notfallmed Schmerzther 1997; 32: 541-548.
25. Anetseder M, Ritter L, Horbaschek H, Hartung E, Roewer N. The impact of 4-chloro-m-cresol in heparin formulas on malignant hyperthermia: in vitro and in vivo. Acta Anaesthesiol Scand 2000; 44: 338-342.
26. Baur CP, Bellon L, Felleiter P, et al, A multicenter study of 4-chloro-m-cresol for diagnosing malignant hyperthermia susceptibility. Anesth Analg 2000; 90: 200-205.
27. Ørding H, Glahn K, Gardi T, Fagerlund T, Bendixen D. 4-Chloro-m-cresol test - a supplementary test for diagnosis of malignant hyperthermia susceptibility. Acta Anaesthesiol Scand 1997; 41: 967-972.
28. Wappler F, Scholz J, Fiege M, et al. 4-Chloro-m-cresol is a trigger of malignant hyperthermia in susceptible swine. Anesthesiology 1999; 90: 1733-1740.
29. Iaizzo PA, Johnson BA, Nagao K, Gallagher WJ. 4-Chloro-m-cresol triggers malignant hyperthermia in susceptible swine at doses greatly exceeding those found in drug preparations. Anesthesiology 1999; 90: 1723-1732.
30. 2+ release channels. Am J Med 1998; 104: 470-486.
31. Jurkatt-Rott K, McCarthy TV, Lehmann-Horn E Genetics and pathogenesis of malignant hyperthermia. Muscle and Nerve 2000; 23: 4-17.
32. Urwyler A, Censier K, Kaufmann M, Drewe J. Genetic effects on the variability of the halothane and caffeine muscle contracture tests. Anesthesiology 1994; 80: 1287-1295.
33. Fiege M, Wappler F, Weißhorn R, et al. The results of contracture tests with halothane, caffeine and ryanodine depend on different malignant hyperthermia associated ryanodine receptor gene mutations. Anesthesiology 2002; 97: 345-350.